Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new ...

Individuals transitioning from multiple daily injections to the Omnipod 5 system experienced an average HbA1c reduction of ...

Participants began with an average HbA1c level of 8.1%. After three months, people who used Omnipod 5 improved HbA1c by an ...

Insulet Corporation’s RADIANT study shows glycaemic improvements with Omnipod 5 automated insulin delivery system: Action, Massachusetts Friday, March 21, 2025, 18:00 Hrs [IST] ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...

Both moves have shown up in margin expansion. Insulet continues to see adoption of its Omnipod 5 pump—the device that represents Insulet's entrance into hybrid closed-loop technology that makes ...

(Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its revolutionary Omnipod 5 Automated Insulin Delivery (AID ...

The study results revealed glycemic improvements using Omnipod 5 compared with insulin injections or pump therapy treatments in adults with type 2 diabetes. The outcome demonstrated significant ...

ACTON, Mass. — Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its ...

Massachusetts-based company's total revenue jumped 17.2per cent to $597.5 million for the quarter ended December 31, beating analysts' estimates of $582.8 million. Sales of Omnipod insulin pumps ...